This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kirtane, A. J. Articles by Carrozza, J. P. Search for Related Content PubMed Articles by Kirtane, A. J. Articles by Carrozza, J. P., Jr

Correlates of Adverse Events During Saphenous Vein Graft Intervention With Distal Embolic Protection

A PRIDE Substudy

Ajay J. Kirtane, MD, SM, FACC^_*, Eugene R. Heyman, PhD, Christopher Metzger, MD, FACC, Jeffrey A. Breall, MD, PhD, FACC, Joseph P. Carrozza, Jr, MD, FACC^||,_*

^_* Center for Interventional Vascular Therapy, Columbia University Medical Center, New York, New York
Montgomery Village, Maryland
The Heart Center, Kingsport, Tennessee
Krannert Institute of Cardiology, Indiana University of Medicine, Indianapolis, Indiana
^|| Section of Interventional Cardiology, Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

View larger version (11K): [in this window] [in a new window] [Download PPT slide]   Figure 1 Association Between Lesion Length and Rates of Adverse Outcomes The figure depicts the relationship between increasing lesion length and the rates of adverse peri-procedural events (major adverse cardiac events [MACE] and creatine kinase-myocardial band [CK-MB] elevation). ULN = upper limit of normal.